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Background: Data modeling techniques can create a virtual world to analyze decision systems. National drug authorities
can use such techniques to take care of their deficiencies in decision making processes. This study was designed to build
a system dynamics model to simulate the effects of market mix variables (5 P’s) on the national drug policy (NDP)
indicators including availability, affordability, quality, and rationality. This was aimed to investigate how to increase the
rationality of decision making, evaluate different alternatives, reduce the costs and identify the system obstacles.
System dynamics is a computer-based approach for analyzing and designing complex systems over time. In this study
the cognitive casualty map was developed to make a concept about the system then the stock-flow model was set up
based on the market demand and supply concept.
Results: The model demonstrates the interdependencies between the NDP variables through four cognitive maps.
Some issues in availability, willingness to pay, rational use and quality of medicines are pointed in the model. The
stock-flow diagram shows how the demand for a medicine is formed and how it is responded through NDP objectives.
The effects of changing variables on the other NDP variables can be studied after running the stock-flow model.
Conclusion: The model can initiate a fundamental structure for analyzing NDP. The conceptual model made a
cognitive map to show many causes’ and effects’ trees and reveals some relations between NDP variables that are
usually forgotten in the medicines affairs. The model also provides an opportunity to be expanded with more details
on a specific disease for better policy making about medication.
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Everyone has the inevitable right to achieve the high
standard health services, thus this is the duty of health
policy makers to promote national drug policies (NDP)
in line with national health objectives [1,2]. The NDP
objectives are defined as making essential quality medicines
available in affordable price for rational use. The NDP as a
framework of integrated activities is influenced by various
factors especially those arisen from inside the government
and the decision making systems. The market-mix var-
iables including product, price, promotion, place and
people are also added to other complexities and issues that
should be taken into account by national drug authorities
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article, unless otherwise stated.The NDP key indicators should be compatible with
health system objectives in terms of effectiveness, financial
fairness and responsiveness. Monitoring the processes and
their results is so essential, however lack of the live key
indicators make it difficult to have a clear picture of the
consequences of decisions made by NDAs [4,5].
The NDA and different parties in the ministry of health
(MOH) have problems in making unified decisions that
would result in amelioration or deterioration of NDP indi-
cators. Surely, the drug systems and decision makers have
limited resources and technologies to predict and evaluate
the consequences of their decisions. Exploring the previous
studies shows a retrospective nature of appraising evidences
and key performance indicators that influence the decision
making processes in the health systems [6]. In fact the
consequences of some NDAs’ decisions are appeared when
it cannot be compensated. To overcome such a deficit in
decision making, the role of simulation systems for solving
the problems is reasonable [7,8].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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therefore, a system thinking approach is needed to analyze
the roles of influencing factors [9]. To enhance the system
efficiency and integrating activities, analysis of processes
and evaluation the negative/positive effects of key variables
must be addressed.
Qualitative and quantitative improvement in health sys-
tem necessitates NDAs to provide higher quality services
but considering government downsizing and budget con-
straints, there is no opportunity to increase human and
capital resources. Therefore, simulation-based systems can
facilitate and accelerate the decision process in order to
help policy makers.
System dynamic (SD) is a modeling concept that sup-
ports decision systems by breaking them into simpler and
smaller subsystems. It helps:
– Shortening the decision process
– Increasing the rationality of actions
– Evaluating the different alternatives
– Reducing the costs
– Decreasing the human-derived mistakes
– Increasing reliability and validity
– Providing potentials for sensitivity analysis and
repeatability.
SD founded by Jay Forrester is used to analyze the
performance of complex systems [10]. It is typically
used for models that represent relationships between
system variables, rates of change over time and unequivo-
cal feedbacks [11].
A rational relationship between the functions of the
NDP core components and market-mixed variables as
the main variables of decision making would enhance
the outcomes and effectiveness of decisions. To use SD
method, it is essential to add some other constant variables
and relations to the model.
Although modeling technique is not a new approach
in policy making, it is new in pharmaceutical affairs
[12,13]. Nowadays there is no such systematic decision
module in Iran while NDAs need such a tool to take
care of deficiencies in decision making process. There
are some negative and positive variables which affect the
NDP. Therefore, building a systemic model can identify,
analyze and monitor the negative/positive effects of influ-
ential factors and at the end reduces the negative effects
and improves positive effects which causes the NDP to
promote.
Taking the case of Iran pharmaceutical sector into
account, we designed this study to analyze the effects of
market mix on the NDP indicators. This study was aimed
to investigate the NDP components, helps to rationalize
activities and decision making, evaluates different alterna-
tives and increases the cost-effectiveness of interventions.Method
In fact SD models are crucial and effective tools for fo-
cusing on stock variables and the flows between them.
Therefore, it seems using SD as a well-adjusted modeling
technique is authentic to respond to the requirements of
this study [14,15].
The model should dynamically and quantitatively simu-
late the core components of NDP (availability, affordability,
quality and rational use). Furthermore, it should reflect the
interactions between the components and the market-mix
variables (price, product, place, people, and promotion).
The model should also address the key influencing factors
for improvement of health policies.
The NDP is composed of four subsystems: availability,
affordability, quality, and rationality. The related variables
were listed (Table 1) and the model was developed in a
deductive basis in three phases:
– Conceptualization: in this phase, the purpose of the
model, the main structure, the boundaries of system
and subsystems were developed and the results were
demonstrated through a casual network or a cognitive
map [16-19]. In addition to the articles and documents,
an expert panel (including three decision maker in IR
FDA, one expert of SD and two pharmacoeconomists)
formed to justify the model.
– Stock-flow modeling: the variables are categorized to
level, auxiliary and constant. Then the adjusted
model and mathematical equations between the
variable were developed. For running the model
Vensim PLE software were used. This software
makes an opportunity to develop and run system
dynamics models in educational or proffessional
level [10,20].
– Testing and sensitivity analysis; the model was
verified and validated to increase the realty of the
simulation. There are some testing methods in SD
that would explain in result part [21-23].
Results
Study area
The NDA in Iran -under supervision of MOH- oversees
and regulates the provision and utilization of medicines
through pharmaceutical division of Food and Drug
Administration (IR FDA). The demand of medicines is
mainly responded through registered products that are
supplied by the public and private manufacturers and
importers. IR FDA follows the generic approach and
tries to protect domestically produced generic medicines
in the market. Two-third of the Iran’s 3.5 billion USD
market has been supplied by local manufacturers. A half
of manufacturers are presented in the stock market and
their main stocks holders are the Social Security Investment
Company, Melli Bank Investing Company and Alborz
Table 1 The list of variables those used in the models’ subsystems (A: Auxiliary, C: Constant variable)
Variable Description Availability Affordability Quality Rationality
1 Affordability Affordability C A
2 Availability of domestic products Availability of domestic products A C
3 Availability of imported products Availability of imported products A C C
4 Brand Strength Dom. Brand Strength domestic products A
5 Brand Strength Imp. Brand Strength imported products A
6 Community promotion Community promotion A
7 Competition Dom. Competition domestic products A A
8 Consumption Dom Consumption domestic products A A
9 Consumption Imp. Consumption imported products A A
10 Cost of production Cost of production A
11 Demand Dom. Demand domestic products A A
12 Demand dom/imp Share of domestic products’ demand A A
13 Demand Imp Demand imported products A A
14 Diagnosis accouracy Diagnosis accouracy A
15 Distributors stock dom. Distributors stock domestic products A
16 Distributors stock Imp Distributors stock imported products A
17 Drug costs Dom. Average costs of domestic products A A
18 Drug costs Imp. Average costs of imported products A A
19 Drug Price Dom. Average price domestic products C C A A
20 Drug price Imp. Average price imported products C C A A
21 Efficacy Efficacy A
22 GDP/Capita GDP per Capita C
23 Global density of pharmacies Average density of pharmacies in the country A
24 Good dispensing practice Good dispensing practice C
25 Good lableing Good lableing C
26 HouseHold costs HouseHold costs C
27 Import Volume of imported products A
28 Importers Number of importers A
29 Income Gross national income per capita C
30 Induced demand Induced demand A A
31 Informed consumer Informed consumer A
32 Intractions Medicinal intractions A
33 Market saturation Market saturation C
34 No. distributors Number of distributors A
35 No. Known Patients Number of known patients A
36 No. pharmacies Number of pharmacies A
37 No. pharmacists Number of pharmacists A
38 No. physicians Number of physicians C
39 No. producers Number of producers A
40 OoP/Household cost OoP/Household cost A
41 OoP/Income OoP/Income A
42 OoP/GDP OoP/GDP A
43 Out of pocket Out of pocket A A
44 Packaging quality Packaging quality A
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Table 1 The list of variables those used in the models’ subsystems (A: Auxiliary, C: Constant variable) (Continued)
45 Patients purchase domestic Patients purchase domestic products A A
46 Patients purchase Imp. Patients purchase imported products A A
47 Pharmacies purchase dom. Pharmacies purchase domestic products A
48 Pharmacies purchase Imp Pharmacies purchase imported products A
49 Pharmacies stock domestic Pharmacies stock domestic products A
50 Pharmacies stock Imp Pharmacies stock imported products A
51 Physicians’ K.A.P. Physicians’ Knoledge/Attitude/practice about rationality A
52 Polypharmacy Polypharmacy A
53 Population Population C
54 Prescriber acceptance Prescriber acceptance A
55 Prescription Prescription A
56 Prescription with injectables Prescription with injections A
57 Prescriptions with Ab Prescriptions with antibiotic A
58 Producer profit Producer profit A
59 Producers’ stock Producers’ stock A
60 Production Production A A
61 Promotion Dom. Promotion on domestic products A A A
62 Promotion Imp. Promotion on imported products A A A
63 Quality budget Dom. Budget for quality improvement of domestic products A
64 Quality budget Imp. Budget for quality improvement of imported products A
65 Quality Dom. Quality index of domestic products C A C
66 Quality Imp. Quality index of imported products C A C
67 R&D budget R&D budget A
68 Rational prescribing Rational prescribing A
69 Rational use Rational use A
70 Rationality Rationality A A
71 Real demand Real demand A
72 Regional density of medical centers Regional density of medical centers A
73 Regional density of pharmacies Regional density of pharmacies A
74 Regulatory power Regualatory power C
75 RX as OTC dispensing RX products without prescription A
76 Safety stock Safety stock C
77 Sales costs Sales costs A
78 Sales value Dom. Sales value of domestic products A A A
79 Sales value Imp. Sales value Imported of products A A A
80 Saving/OOP Saving/OOP A
81 Self-treatment Self-treatment A
82 Side effects Side effects A
83 Social information Social information A
84 Stock imported Stock of imported products A
85 Total demand Total demand A A A
86 Treatment Treatment A A A
87 User stock Dom. Stock of domestic products in homes A
88 User stock Imp. Stock of imported products in homes A
89 Waste & Exp. Dom. Waste & expired domestic products A
Abdollahiasl et al. DARU Journal of Pharmaceutical Sciences 2014, 22:34 Page 4 of 13
http://www.darujps.com/content/22/1/34
Table 1 The list of variables those used in the models’ subsystems (A: Auxiliary, C: Constant variable) (Continued)
90 Waste & Exp. Imp. Waste & expired imported products A
91 Willing to use Willing to use A
















Figure 1 The primary summarized conceptual model for main
variables in NDP.
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companies and the most importers are owned by private
sectors. There are tens of distributors that distribute
medicines around the country but the top five covers
about 80 percent of the market. The price of all medicines
is set by the government through the commission of pri-
cing in IR FDA. The official method of pricing is cost-plus
for generic medicines and external reference pricing for
branded products; although some country-specific factors
such as market size, anti-inflation policies, national eco-
nomics and some political issues are determinants. Clinical
services are provided by both public and private sectors but
patients pay the same price for medicines in both sectors.
The majority of the people are covered for their treatment
costs by three main basic health insurers; they cover about
45 percent of health costs. The medication costs for certain
illness including AIDS, TB, Malaria, Hemophilia, Thalase-
mia, transplantation and vaccination are covered totally by
the MOH [24]. The survey on access to medicines found
that most general medicines are available and affordable
for all - the lowest paid workers as indicator- in both
public and private sectors [25,26].
Logical framework of the model
Our suggested SD conceptual model is composed of two
subsystems: NDP objectives and market mix variables.
NDP is aimed to improve quality of human life mainly by
equitable providing affordable quality drugs for patients
who rationally need them. Market mix (5 P’s) are compo-
nents of a market that are aimed by marketing strategies.
The interaction between NDP objectives and market mix
components shaped the framework of the model.
Health system is too wide and complicated to be mod-
eled completely in a detailed study; the framework of
the model determines how deep the model is supposed
to study interactions between NDP and market mix. For
exploring the interactions among the variables a SD
model is proposed which mainly was structured on the
demand of medicines.
Firstly, a summarized cognitive map of causal loops
was described (Figure 1). As mentioned before, the NDP
objectives play an important role in helping the policy
makers to determine the demand of patients’ medicines.
Therefore, the twelve main variables -Affordability,
Availability, Consumption, Demand, Distribution-Points,
Price, Product Supply, Promotion, Quality, Rationality,
Treatment, Willingness to pay (WTP)- formed an overview
on the system through the sixteen causal loops. But it wastotally obvious that many other variables should be defined
to justify the model. All relations in primary structure
expanded to a network of variables; to justify the sub-
systems some other constant or auxiliary variables were
added to the model (Figure 2). The expanded model is a
casual network that shows the relationships between all
variables in NDP. This vast model is for demonstrating
the complexity of the system and is essential to break it
to smaller parts for detailed analysis.
In Iran, there are two different governmental approaches
against imported medicines and domestically produced
ones, therefore it was tried to consider these two ap-
proaches in studying the main NDP variables. The nature
of the model leads to study it in two parts; the conceptual
cognitive map was explored in part 1 and quantifying the
variables and running their relationships are explained in
part 2 in a stock-flow model.
Part 1–1: Availability
According to the logical framework of NDP, the causal
diagram of the availability was designed based on two
approaches; domestically produced products and imported
ones (Figure 3). Availability has been defined as having the
essential stock of the product in determined distribution
points [1]. Then the number of pharmacies who distribute
































































































































































































































































































































































































































































































































































Figure 3 The conceptual model for availability.



















Figure 4 The causes tree for “out of pocket”.
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level of availability. In the model, both availability variables
are placed in two loops that are balanced with patient
purchase and pharmacy stock. Pharmacy stock for both
domestic and imported product is a part of medicines
supply chain which is affected by distributors’ stock
and purchase, production, and importation. Patients
purchase is influenced by medicines consumption cycles
while affordability and WTP are two main variables in
these cycles. There is a variable named “demand dom/
imp” that shows the ratio of domestically produced product
in the market from demand side. This item would balance
the availability level of domestically produced medicines
versus imported ones.
The other variables which affect the availability loops
through the patients purchase are medicines’ stock in
patient’s homes and in hospital wards; also the waste
and expired medicines are effective.
The other issue in availability is “medical malls” that
are places that all medical facilities and physicians’ offices
have been concentrated in; based on the current regula-
tions, the number of pharmacies as the dispensing places
of medicines is a function of population, distance to other
pharmacies and density of medical centers. Medical malls
are ideal locations for founding pharmacies but they are
against the physical availability of medicines. The IR FDA
as the authorized organization for regulating pharmacies
allows increasing the number of pharmacies in these
regions regardless to the distance to promote the fair
income of pharmacies. It makes a reinforced loop to gather
more medical firms in such areas and decrease the uniform
distribution of pharmacies around the cities; then the level
of availability declines.
Availability is not only an essential factor for access to
medicines but it can induce the demand in the market.
High level of stock which is in favor of availability would
increase the financial costs of suppliers then they increase
their sales forces whenever they are overstocked; this is
one of the causes of the induced demand. Although in the
market the data of demand direct the supply, the role of
potential market could not be ignored. Potential market
that we showed it in the model as “market saturation
ratio” is the extra stock of a medicine that should be
supplied in addition to real demand for market confidence.
“Market saturation” variable that directly related to the
safety stock of a medicine in the country, is affecting sig-
nificantly on other main variable in the model.
Part 1–2: affordability
Affordability as having enough money to pay for the
medicines has involved many contributors in health system.
Out of pocket (OOP) /household costs, OOP/income and
OOP/gross domestic products (GDP) per capita are three
indicators used to show the affordability of medicinesin the model. The coverage of basic and complementary
insurances for in-patients and out-patients, the government
subsidy on some products such as antihemophilic factors
and Iron chelators for Thalassemia, and different pricing
approach for over the counter (OTC) medicines are affect-
ing affordability through “out of pocket” (Figure 4).
Although affordability is an important factor to purchase
medicines, the role of willingness to pay (WTP) should take
into account. Family and social knowledge, promotional
activities by suppliers, country and family economical
situation, severity of illness and the opportunity costs
for medication (the alternative treatments that may exist)
tend patients to pay more/less for medicines (Figure 5).
Despite of different policies against domestic and
imported medicines, there are more balanced (negative)
than reinforced (positive) loops in this part of the model;
all variables that could increase patients’ OOP, would be
balanced through reduction of affordability (Figure 6).
Prices of domestic and imported drugs that are the most
important inputs of affordability loops are the output of
suppliers’ requests and negotiation power of the NDA
against price increase. The price variables in addition to
increase of OOP, can be input of the quality system through
sales increase.Part 1–3: quality
The quality of medicines not only initiates their safety,
efficacy, WTP and patient acceptance but also affects on
their share in the market. A wide range of variables in-
fluence the quality of domestically produced medicines
but a few factors could affect the quality of imported
ones (Figure 7). Because NDA has no complete control
on the quality of imported medicines in production level
in the country of origin, completing registration process
and enforcing post marketing quality controls are two
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Figure 5 The causes tree for “willingness to pay”.
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http://www.darujps.com/content/22/1/34The quality of domestic products placed in two feedback
loops: the main balanced loop comes from the cost of
quality which increases the cost of production and leads
to decrease the quality budget due to the profit reduction.






























Figure 6 The conceptual model based on affordability.increase of demand, sales and market share due to the
quality. For imported medicines, there is an only reinforced
loop coming from investing on the post manufacturing
quality controls and quality promotion (Figure 8).
The role of NDA is crucial in improving quality; NDA
can promote the concept of quality management in local
pharmaceutical companies, create the opportunity for
investing on the quality with rationalizing the prices,
regulating and auditing good manufacturing/distribut-
ing/storage/laboratory practices in drug supply chain,
empowering registration process and post marketing
quality control practices.
Part 1–4: rational use
Rational drug use as an important pillar of NDP could clin-
ically, socially, and economically help the health system. In
this model rational prescribing, good dispensing practice
and giving information to patients are the main determi-
nants of rationality. All promotional and advertising activ-
ities not only affect on the public health but also change
the demand and subsequently modify activities of supply













































Figure 7 The causes tree for quality.
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http://www.darujps.com/content/22/1/34positive loops (Figure 9). Because there is an information
asymmetry in health system, all activities that improve social
information about the medicines and change knowledge,
attitude and practice of practitioners can positively affect


























Figure 8 The conceptual model for quality.Part 1–5: Other important variables
There are some other variables in the model including
population, birth and death rate, total demand, responded
demand, epidemiological indices, number of physicians and
pharmacists and diagnosis accuracy that help to complete
system for simulation. Although treatment of patients is
the main objective of medication, right diagnose, patient
compliance, efficacy and side effects can change the treat-
ment progress. Consuming the medicine is not the end of
the treatment chain, many chronic diseases are never
cured and patients should consume their medicine forever
to control the progress of the disease or improve their
quality of lives; thus they always stay on the medicine
demand cycle. In spite of the demand for main illness
treatment, treating the side effects and new sicknesses
have some other negative forces on the treatment cycle
and leads to new demands. The patients’ death in chronic
diseases and healing in acute ones removes the patients
from the treatment cycle and reduce the demand.
Part 2–1: The stock-flow model
Figure 10 shows the stock flow diagram developed based
on the mentioned conceptual casualty network. Population,
demand and stock are three bunches of stock variables
in the model. Population has divided into four stock
variables due to age structure of the country. The inci-
dence rates for each age group, the diagnosis rate and
the standard dose of medicine would project the num-
ber of susceptible people for treatment that makes the
demand. The unit used for demand variables was de-






















































































































Figure 9 The conceptual model for rationality.
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purchased and consumed -will move to the variable
named “responded demand” (Figure 10). Death and
stopping treatment are the exit ways of this stock variable
for chronic patients; treating rate is the other exit way for
acute ones.
All domestic producers and importers collect their
supplied medicine in a stock variable called medicine
stock. The level of medicine stock variable is higher
than the demand based on market saturation rate. The
variable “Medicine stock” has two existence way; all
demands that can be responded including new demands
and current chronic consumers would reduce the medicinestock through these existence ways called “purchase rates”
channels. The purchase rate has made by affordability,
availability and WTP.
The quality and rationality related variables put their
effects on auxiliary variables called “stop rate” that reduce
the number of current consumers.
The variables, their units and the equations were
defined on Vensim PLE (academic version) and the model
was executed for a 120 months period.
The model was run without any mistakes and the influ-
ence of any changes on any variables could be explored on
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Figure 10 The stock flow model for NDP.
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There are a wide variety of tests for verification and
validation of SD models. To assess the structure, dimen-
sional consistency, extreme conditions and robustness of
equations under stress situations are used. For testing
behavior reproduction the pattern of outputs are com-
pared with real data. Then the model was tested not only
for outputs but also for internal structure [23]. Direct
structure tests including extreme-conditions and dimen-
sional consistency was done on all major variables by the
software (Vensim). Also the expert panel of the study was
revising the structure and casualty relations for many
times to reach to the optimum situation.
For testing the structure behavior, some major variables
including population groups were compared to real data
but for some variables we had no real data for comparing
and the expert panel tried to justify them.
Because the concept of modeling in NDP is new in
Iran and there are a few written documents about it,
reaching to a consensus in the expert panel on the result
of the model was difficult; it is challengeable for other
experts yet. Some extreme and different conditions that
the model tested on them were acute versus chronic,
high prevalence versus rare disease, cheap versus expensive
treatment and rational high quality drugs versus irrational
low quality.Although for testing the validity, a kind of sensitivity
analysis was done but for performing sensitivity analysis
all rate variables and initial values are changed in a wide
range (even wider than real situation) and the behavior
of the model and the value of other major variables were
studied. Because there are a lot of variables in the model
that should be adjusted with a specific disease and its
major treatments, the range of the variables’ value signifi-
cantly depend on the value of other variables. For example
if we adjust the model with a rare congenital disease with
a full subsidized medicines, availability, affordability and
quality variables in the model is no sensitive to the ex-
work price or death rate of adults; but it is hugely sensitive
to the birth rate.
Discussion
The model is targeted to help policy makers as a decision
support system (DSS) with analyzing interrelationships
between availability, affordability, quality and rational use
of medicines. The casual network was formed by about
140 selected variables made a crowded cognitive map in
the conceptual phase that was too complex to interpret so
it forced the model to break into four main subsystems.
The challenges developed in defining the borders of the
subsystems, caused some intersectional variables to be
repeated in more than one subsystem.
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mand and supply concept. This demand was made by
the population structure and incidence rates. We had
to break the population to four stock variables due to
the population structure of Iran. Because of the lack of
disease epidemiology data in Iran we used any data
from any country for covering incidence rates. It was
thought this lack of data could be covered by the ability
that is in SD to do a wide range of sensitivity analysis.
The supply side was summarized to a few level and
auxiliary variables that comes to the model as input
variables, then it can be expanded to more detailed models
in supplementary studies.
Availability subsystem consists of the supply side of
the stock-flow model and number of pharmacies as the
constant variable; although increasing the number of
pharmacies can improve the availability, it cannot over-
whelm the total stock situation; the total stock of the
modeled medicine comes from the total demand through
domestically production and imports. The number of
pharmacies under the control of the government has a
slow growth due to low population growth rate.
The insurance system and subsidization that play the
main role in affordability subsystem present themselves
as two constant variables in the stock-flow diagram. The
role of insurance organizations can be explained based
on the other variables in health financial system. There is
a stock variable in the model that shows the cumulative
medication costs of the illness and demonstrates the time
when patients could fall in catastrophic expenses. The
model shows only cancer and autoimmune patients can
fall in the catastrophic expenses; medication for normal
high burden diseases including cardiovascular, diabetes,
central nervous disorders and gastro intestinal are too
cheap to send patients to financial failure.
Quality and rationality in the stock-flow diagram are
not in the core of the model; they can just affect the
model as a foreign control knob.
It was attempted to use mathematical equations between
variables than regression equations. Thus, we had to select
some variables that can be adopted with it.
Conclusion
The model can initiate a fundamental structure for ana-
lyzing NDP. The conceptual model made a cognitive
map for NDP that not only shows many causes and effects
trees but also reveals some relations between NDP var-
iables that are usually forgotten or ignored in the med-
icines affairs:
– The role of centralized medical centers in reducing
the availability of medicines; although the model is
silent on the effects of reducing profit of pharmacies
on availability [28].– It had already been demonstrated the increasing
share of imported medicines in the market [29] but
this study demonstrates the influence of importers’
promotional activities on expanding the market and
quality of domestically produced medicines.
– The effects of the patients’ WTP on purchasing
their medicines and the demand for the medicine.
– The bigger role of prescriber than consumer in
rational use of medicines.
– The mutual effects of overstocking in domestic or
imported products on supplying and promotion
activities.
– The influence of quality and rational use on the
patients’ willingness to use.
There are also some special points in the model that
play significant roles in the NDP that should be more
notified:
– The amount of medicines that stocked in patients’
homes. It can be the reason that the sales of
pharmaceutical usually have no direct relation to
health indices [30].
– The effects of medication on the population groups.
– The effect of brand names on the quality.
– The influence of regulatory power on the quality
and the supply of medicines that was also explained
in other studies [31,32].
Overall this model provides 52 control knobs for the
modeler to adjust the model with a selected medicine in
a specific disease. Then 121 level and auxiliary variable
trends can clarify the consequences of any changes before
making any decisions in the NDA.
Linking this model to some real live epidemiological
and disease surveillance databases in the country could
create a decision support system to help decision making.
The stock-flow model not only shows some relations
between NDP variables but provide a framework for other
more detailed studies.
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